Memo Therapeutics AG presented complete Phase II data for potravitug, a drug targeting BK polyomavirus (BKPyV) in kidney transplant recipients, at the American Transplant Congress 2026. The SAFE KIDNEY II trial showed potravitug significantly reduced viral load and biopsy-proven BKPyV-associated nephropathy up to 38 weeks post-treatment, with 24.4% of treated patients achieving undetectable viral DNA versus 13.0% on placebo. The drug was well tolerated with no serious adverse events. These results support potravitug as a potential first-in-class therapy, with a Phase III trial planned for later in 2026 and orphan drug designation granted in the EU.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
